Young Comments on New Government Requirements On Duke University Researchers Who Receive Federal Funds
23 March 2018
Senior Counsel Torrey Young is quoted in a Science magazine article, “Duke’s mishandling of misconduct prompts new U.S. government grant oversight,” about new National Institutes of Health requirements on university-based research in response to concerns about the institution’s handling of recent research misconduct and grant management cases.
Young, who has represented a number of institutions in matters involving research misconduct and grants accounting, said she believes the action is a “fairly rare and extensive” move on the NIH’s part.
“These additional administrative burdens potentially could delay funding and extensions, as well as significantly increase duties for Duke’s Office of Research Support,” she said. “This may also lead to reputational harm to the institution, leading to difficulty recruiting researchers.”
Young, who has represented a number of institutions in matters involving research misconduct and grants accounting, said she believes the action is a “fairly rare and extensive” move on the NIH’s part.
“These additional administrative burdens potentially could delay funding and extensions, as well as significantly increase duties for Duke’s Office of Research Support,” she said. “This may also lead to reputational harm to the institution, leading to difficulty recruiting researchers.”
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”